title: Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
abstract: A major obstacle to using next generation sequencing (NGS) technology in clinical routine practice is reliable data analysis. Thousands of sequences need to be aligned and validated, to exclude sequencing artifacts and generate accurate results. We compared two analysis pipelines for Roche 454 ultradeep pyrosequencing (UDPS) raw data generated from HIV-1 clinical samples: a commercial and fully automated Web-based software NGS HIV-1 Module (SmartGene, Zug, Switzerland) vs. the Amplicon Variant Analyzer software (AVA, 454 Life Sciences; Roche). Results were also compared to those obtained with Sanger sequencing. HIV-1 reverse transcriptase and protease genes from 34 plasma samples were submitted to Sanger sequencing and GS Junior UDPS. Raw UDPS data (sff files) from all samples were analyzed with AVA 2.7 software plus manual review of the alignments and the fully automated SmartGene NGS HIV-1 Module prototype (SMG). Results obtained with both analysis pipelines showed good correlation (85.0%). Divergent results were mainly observed at homopolymer positions, such as K101, where the frame-aware alignment and error corrections of the automated approach were more efficient and more accurate, both in terms of detecting and quantifying drug resistance mutations. Our study shows that NGS data can easily be analyzed via a fully automated analysis pipeline, here the SmartGene NGS HIV-1 Module, thus minimizing the need for manual review of alignments by the user, otherwise essential to ensure accurate results. Such automated analysis pipelines may facilitate the adoption of NGS platforms in the routine clinical laboratory.
authors.affiliation: 1 CNRS-UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université Bordeaux Segalen , Bordeaux, France .|2 Centre Hospitalier Universitaire de Bordeaux (CHU) , Laboratoire de Virologie, Bordeaux, France .
authors.forename: Pantxika
authors.initials: P
authors.lastname: Bellecave
authors.affiliation: 1 CNRS-UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université Bordeaux Segalen , Bordeaux, France .|2 Centre Hospitalier Universitaire de Bordeaux (CHU) , Laboratoire de Virologie, Bordeaux, France .
authors.forename: Patricia
authors.initials: P
authors.lastname: Recordon-Pinson
authors.affiliation: 1 CNRS-UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université Bordeaux Segalen , Bordeaux, France .|2 Centre Hospitalier Universitaire de Bordeaux (CHU) , Laboratoire de Virologie, Bordeaux, France .
authors.forename: Hervé
authors.initials: H
authors.lastname: Fleury
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology; D057205:Automation, Laboratory; D001483:Base Sequence; D024882:Drug Resistance, Viral / Q000235:genetics*; D015870:Gene Expression; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000254:growth & development; D059014:High-Throughput Nucleotide Sequencing / Q000295:instrumentation / Q000379:methods*; D006761:Hospitals; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation; D048348:Reverse Transcription; D016415:Sequence Alignment; D012984:Software; D019562:Viral Load / Q000235:genetics
chemical_list: D019380:Anti-HIV Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1